Quick and easy sterile connections for single-use biopharmaceutical processing
AseptiQuik® connectors from CPC provide easy and reliable sterile connections for single-use biopharmaceutical processing. Robust designs for 1/8®(3.2mm) to 1? (26.4mm) quickly transfer valuable media. Read the white paper.
Quick and easy sterile connections for single-use biopharmaceutical processing
AseptiQuik® connectors from CPC make single-use sterile connections faster, easier and safer than ever before. Robust, easy-to-use connector designs enable users to quickly transfer valuable media with more confidence and less risk of operator error. AseptiQuik® connectors provide reliable, sterile connections without the need for clamps, fixtures or tube welding.
The newest addition to CPC’s sterile connection technologies, genderless AseptiQuik® G connectors simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector—systems are more flexible and minimize supply chain complexity.
The AseptiQuik family offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2mm to 25.4mm (1/8” to 1”). AseptiQuik’s are ideal for applications where reliability and sterility are a must—including single-use bag and tubing assemblies, cell banking systems, bioreactors, mixers, sampling, formulation and filling. White paper: "How single-use connections advance aseptic processing"
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
